Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 8/20 | 0.53 |
| ▸ | SCN5A | Q14524 | 6/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.36 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.36 |
| ▸ | ABL1 | P00519 | 2/20 | 0.36 |
| ▸ | FYN | P06241 | 4/20 | 0.35 |
| ▸ | SCN1A | P35498 | 1/20 | 0.35 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20204051 | 0.91 | CYP1A2 (0.61) | CYP1A2SCN5ASCN1ASCN2A | |
| SCHEMBL26539431 | 0.89 | CYP1A2 (0.54) | CYP1A2SCN5ACHEK1CHEK2ABL1 | |
| SCHEMBL26539468 | 0.86 | CYP1A2 (0.59) | CYP1A2SCN5ACHEK1CHEK2ABL1 | |
| SCHEMBL26539469 | 0.84 | CYP1A2 (0.53) | CYP1A2SCN5ACHEK1CHEK2ABL1 | |
| SCHEMBL26540171 | 0.82 | CYP1A2 (0.62) | CYP1A2SCN5ASCN1ASCN2A | |
| SCHEMBL23571348 | 0.81 | CYP1A2 (0.52) | CYP1A2SCN5ACHEK1CHEK2ABL1 | |
| SCHEMBL20203911 | 0.81 | CYP1A2 (0.64) | CYP1A2SCN5AFYNSCN1ASCN2A | |
| SCHEMBL26539143 | 0.81 | CYP1A2 (0.61) | CYP1A2SCN5AFYNSCN1ASCN2A | |
| SCHEMBL26539108 | 0.80 | CYP1A2 (0.59) | CYP1A2SCN5ASCN1ASCN2A | |
| SCHEMBL26328989 | 0.79 | CYP1A2 (0.50) | CYP1A2SCN5ACHEK1CHEK2ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322790-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322790-A1 | COMPOUNDS AND THEIR METHODS OF USE | SCN1A, SCN3A, SCN1B | CYP1A2 1988/4885SCN5A 8/4885CHEK1 4715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.